CoChat
Sign Up
Cited by 525Treatment of Major DepressionElectroconvulsive Therapy StudiesTryptophan and brain disorders

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression.

Open access
Singh, Jaskaran B., Fedgchin, Maggie, Daly, Ella J., De Boer, Peter, Cooper, Kimberly, Lim, Pilar, Pinter, Christine, Murrough, James W., Sanacora, Gerard, Shelton, Richard C., Kurian, Benji, Winokur, Andrew, Fava, Maurizio, Manji, Husseini, Drevets, Wayne C., Van Nueten, Luc·2016·American Journal of Psychiatry
DOI 10.1176/appi.ajp.2016.16010037
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated the efficacy of twice- and thrice-weekly intravenous administration of ketamine in sustaining initial antidepressant effects in patients with treatment-resistant depression. METHOD: In a multicenter, double-blind study, adults (ages 18-64 years) with treatment-resistant depression were randomized to receive either intravenous ketamine (0.5 mg/kg of body weight) or intravenous placebo, administered over 40 minutes, either two or three times weekly, for up to 4 weeks. Patients who discontinued double-blind treatment after at least 2 weeks for lack of efficacy could enter an optional 2-week open-label phase to receive ketamine with the same frequency as in the double-blind phase. The primary outcome measure was change from baseline to day 15 in total score on the Montgomery-Åsberg Depression Rating Scale (MADRS). RESULTS: In total, 67 (45 women) of 68 randomized patients received treatment. In the twice-weekly dosing groups, the mean change in MADRS score at day 15 was -18.4 (SD=12.0) for ketamine and -5.7 (SD=10.2) for placebo; in the thrice-weekly groups, it was -17.7 (SD=7.3) for ketamine and -3.1 (SD=5.7) for placebo. Similar observations were noted for ketamine during the open-label phase (twice-weekly, -12.2 [SD=12.8] on day 4; thrice-weekly, -14.0 [SD=12.5] on day 5). Both regimens were generally well tolerated. Headache, anxiety, dissociation, nausea, and dizziness were the most common (≥20%) treatment-emergent adverse events. Dissociative symptoms occurred transiently and attenuated with repeated dosing. CONCLUSIONS: Twice-weekly and thrice-weekly administration of ketamine at 0.5 mg/kg similarly maintained antidepressant efficacy over 15 days.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2016.16010037

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 4

  1. Slatkin NE, 2003, J Support Oncol, 1, 287
  2. Sheehan DV, 1998, J Clin Psychiatry, 59, 22
  3. 10.1111/j.1755-5949.2008.00038.x · DOI
  4. Busner J, 2007, Psychiatry (Edgmont), 4, 28

Cited by

Sorted by citations

Items 501–524 of 524

Related

See all

Metadata

Authors
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., Kurian, B., Winokur, A., Fava, M., Manji, H., Drevets, W. C., & Van Nueten, L.
Affiliations
  • University of Alabama at Birmingham (US)
  • From Janssen Research and Development, Titusville, N.J., and Beerse, Belgium; the Departments of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, N.Y.; the Department of Psychiatry, Yale University, New Haven, Conn.; the Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama at Birmingham; the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas; the Institute of Living, Hartford, Conn.; University of...
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2016-08-01
Volume
173
Issue
8
Pages
816-826
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/appi.ajp.2016.16010037
OpenAlex
W2330587564
Semantic Scholar
2883380785205ffb1f72303d5b51284fb5d21c95
Cited by
525
References
20
Citations by year
2026: 23 · 2025: 47 · 2024: 47 · 2023: 51 · 2022: 65 · 2021: 65 · 2020: 72 · 2019: 47 · 2018: 49 · 2017: 38 · 2016: 19
FWCI
41.23
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Sanofi
  • Yale University
  • Biogen
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Stanley Medical Research Institute
  • Icahn School of Medicine at Mount Sinai
  • Sunovion
  • Indivior
  • Cerecor
  • American Society of Clinical Psychopharmacology
  • FORUM Pharmaceuticals
  • Belvoir Media Group
  • Vistagen Therapeutics
  • Servier
  • H. Lundbeck A/S
  • National Institutes of Health
  • Genentech
  • St. Jude Medical
  • Allergan
  • National Institute of Mental Health
  • National Institute on Drug Abuse
  • National Center for Complementary and Alternative Medicine
  • Janssen Research and Development
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ketamine, treatment-resistant depression, intravenous administration, dosing frequency, antidepressant efficacy, NMDA receptor antagonists, dissociation, adverse events, open-label extension
MeSH terms
Adolescent, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Humans, Infusions, Intravenous, Ketamine, Middle Aged, Psychiatric Status Rating Scales, Psychometrics, Young Adult, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review